Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCTIC in previously treated advanced non-small cell lung cancer
2014-000338-46Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2014
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by AstraZeneca. Primary endpoints: Overall survival and Progression-free survival. Started Jul 2014; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-000338-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000338-46.